129250-89-1

Usage

Uses

Used in Pharmaceutical Industry:
3-(BROMOMETHYL)PHENYL BENZOATE is used as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving existing ones.
Used in Agrochemical Industry:
3-(BROMOMETHYL)PHENYL BENZOATE is used as a precursor in the production of agrochemicals, such as pesticides and herbicides, enhancing crop protection and yield.
Used in Materials Science:
3-(BROMOMETHYL)PHENYL BENZOATE is utilized in the development of new materials with specific properties, such as polymers, coatings, and adhesives, for various applications.
Used in Research and Development:
3-(BROMOMETHYL)PHENYL BENZOATE is employed as a starting material for the synthesis of novel compounds, facilitating scientific exploration and innovation in the chemical field.
Used in Antimicrobial Applications:
3-(BROMOMETHYL)PHENYL BENZOATE may be used as an antimicrobial agent, potentially inhibiting the growth of bacteria and other microorganisms, due to its chemical structure.
Used in Antifungal Applications:
3-(BROMOMETHYL)PHENYL BENZOATE may also serve as an antifungal agent, preventing the growth of fungi and protecting materials or products from fungal contamination.
Used in Antioxidant Applications:
3-(BROMOMETHYL)PHENYL BENZOATE could be utilized as an antioxidant, neutralizing free radicals and preventing oxidative damage in various industrial processes or products.

Upstream product

• 614-32-4 3-methylphenyl benzoate 
• 98-88-4 benzoyl chloride 
• 108-39-4 3-methyl-phenol 

Downstream Products

• 744261-83-4 Benzoic acid 3-(6-amino-purin-9-ylmethyl)-phenyl ester 
• 129250-87-9 1-(3-Hydroxybenzyl)thymine 
• 129250-85-7 9-(3-Hydroxybenzyl)adenine 
• 129250-86-8 9-[3-(12-Bromo-dodecyloxy)-benzyl]-9H-purin-6-ylamine 
• 129250-88-0 1-(3-{12-[3-(6-Amino-purin-9-ylmethyl)-phenoxy]-dodecyloxy}-benzyl)-5-methyl-1H-pyrimidine-2,4-dione 
• 1361296-32-3 N-oxalyl-S-(3-hydroxybenzyl)-L-cysteine 

Relevant academic research and scientific papers

Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: Development and biopharmacological profiling of 7-[(3-chlorobenzyl) oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor

In an effort to discover novel selective monoamine oxidase (MAO) B inhibitors with favorable physicochemical and pharmacokinetic profiles, 7-[(m-halogeno)benzyloxy]coumarins bearing properly selected polar substituents at position 4 were designed, synthesized, and evaluated as MAO inhibitors. Several compounds with MAO-B inhibitory activity in the nanomolar range and excellent MAO-B selectivity (selectivity index SI > 400) were identified. Structure-affinity relationships and docking simulations provided valuable insights into the enzyme-inhibitor binding interactions at position 4, which has been poorly explored. Furthermore, computational and experimental studies led to the identification and biopharmacological characterization of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)-methyl]-2H-chromen-2-one methanesulfonate 22b (NW-1772) as an in vitro and in vivo potent and selective MAO-B inhibitor, with rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. On the basis of this preliminary preclinical profile, inhibitor 22b might be viewed as a promising clinical candidate for the treatment of neurodegenerative diseases.

Inhibition of monoamine oxidases by functionalized coumarin derivatives: Biological activities, QSARs, and 3D-QSARs

A large series of coumarin derivatives (71 compounds) were tested for their monoamine oxidase A and B (MAO-A and MAO-B) inhibitory activity. Most of the compounds acted preferentially on MAO-B with IC50 values in the micromolar to low-nanomolar range; high inhibitory activities toward MAO-A were also measured for sulfonic acid esters. The most active compound was 7-[(3,4-difluorobenzyl)oxy]-3,4-dimethylcoumarin, with an IC50 value toward MAO-B of 1.14 nM. A QSAR study of 7-X-benzyloxy meta-substituted 3,4-dimethylcoumarin derivatives acting on MAO-B yielded good statistical results (q2 = 0.72, r2 = 0.86), revealing the importance of lipophilic interactions in modulating the inhibition and excluding any dependence on electronic properties. CoMFA was performed on two data sets of MAO-A and MAO-B inhibitors. The GOLPE procedure, with variable selection criteria, was applied to improve the predictivity of the models and to facilitate the graphical interpretation of results.

Antiosteoporotic imidazo[4,5-c]pyridines

This invention relates to 2-substituted-imidazo[4,5 -c]pyridines, to the process for their preparation, to pharmaceutical compositions containing said 2-substituted-imidazo]4,5-c]pyridines and to the use of said 2-substituted-imidazo[4,5-c]pyridines for modifying the balance between bone production and bone resorption in a host animal, including man.

Preparation of an intramolecular adenine-thymine base pair

An intramolecular adenine-thymine derivative 5, prepared by connecting 9-(3-hydroxybenzyl)adenine and 1-(3-hydroxybenzyl)thymine with a dodecamethylene bridge via ether linkages, undergoes intramolecular adenine-thymine base pairing via hydrogen bonding i